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Introduction
The coeliac disease (CD) is an immune-mediat-
ed enteropathy triggered by an ingestion of
gluten in genetically susceptible individuals (1,
2). It is one of the most commonly chronic dis-
eases found in Caucasians, with a frequency in
the general population between 1:85 and 1:300,
both in Europe and in United States (3, 4). Over
the last thirty years, the incidence of CD has sig-
nificantly increased, as a probable consequence
of the improvement in the diagnosis of atypical
forms, confirming today the prevalence between
0.7% and 2% (5). 
Like some other systemic diseases (Crohn’s dis-
ease, Sjögren’s syndrome) the CD is able to alter
the oral ecosystem and the composition of the
saliva (6, 7). In fact it has been observed that in
subjects suffering from CD it’s produced a lower
amounts of amylase, secretory IgA and IgM com-
pared to those found in the saliva of healthy sub-
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SUMMARY
The coeliac disease is an immune-mediated enteropathy triggered by an ingestion of gluten in genetically sus-
ceptible individuals. Like some other systemic diseases (Crohn’s disease, Sjögren’s syndrome) the celiac dis-
ease is able to alter the oral ecosystem and the composition of the saliva.
Aim. The aim of this retrospective study has been to examine the incidence of coeliac disease (CD) in paediatric popu-
lation and to search the presence of anti-transglutaminase auto-antibodies (anti-tTG) in saliva, comparing and quantify-
ing the concentration regard to the serum values of the anti-tTG auto-antibodies, before and after six months from the
beginning of the free gluten diet.
Materials and Methods. 105 children (G
0
), aged between 5 and 13 years, belonging to the Paediatric Gastroenterology-
Endoscopy Unit of PTV Hospital, University of Rome “Tor Vergata”, have been examined for a diagnosis of suspected CD. 
Results. Of a total of 105 pediatric patients (G
0
), only the 16.2% (G
1
) has showed to be positive. About the evaluation of
the anti-tTG auto-antibodies in the serum, obtained from the second blood sample (T
1
), we can observe that 10 (G
2
) out
of 17 children (G
1
) show positivity and for this reason they have been subjected to a sampling of intestinal villi to confirm
the diagnosis of CD; in addition the 6.7% has been resulted positive at the first sampling of serum (T
0
), but negative to
the second one (T
1
). The incidence of the CD has been resulted to be equal to 9.5%. About the evaluation of anti-tTG in
the G1, we can observe that 58.8% of children are “definitely positive” to the salivary anti-tTG, while 11.8% appear to be
weakly positive. About the correspondence of serum and salivary anti-tTG in Group G1, we can observe, that children
positive to the anti-tTG in the serum have also the anti-tTG in the salivary fluid (sensibility 100%, specificity 71.4%). The
results show that the anti-tTG salivary are present in children with CD, even though they have continued to follow the gluten
free diet for 6 months.
Conclusions. The presence of anti-tTG in the saliva may be considered, an additional and useful diagnostic dental marker
for an initial, reproducible, non invasive, inexpensive and highly sensitive screening of CD having a predictive and pre-
cocious value compared to anti-tTG contained in the serum, as it has been already demonstrated.
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jects (8, 9). In addition, some significant differ-
ences have been detected between the chemical
composition of the saliva in the coeliac subjects
and that of healthy subjects, as regards: the
buffering capacity, the speed of salivary flow, the
concentration of calcium, the Ca/P ratio (6, 10).
Recently it has been observed that in the saliva
of coeliac subjects there are anti-transglutami-
nase (anti-tTG) auto-antibodies, whose blood re-
search, until now, it has been considered the
more reliable, simple and less invasive method
of the screening protocol of CD (11).
Therefore, the aim of this retrospective study has
been to examine the incidence of CD in paedi-
atric population and to research in the group of
children positive resulted to the first blood sam-
ple, the presence of anti-tTG auto-antibodies
even in saliva, comparing and quantifying the
concentration compared to the values got by a
second blood sample.
In addition, we have evaluated the significant
differences in the concentrations of anti-tTG au-
to-antibodies in the saliva, before and after the
beginning of the free gluten diet, both in subjects
positive resulted at the second blood sample and
to a sampling of intestinal villi, that in children
negative resulted at the second blood sample but
positive to the first one, and therefore considered
potentially coeliac.
Materials and methods
Between March and October 2011, it has been ex-
amined a group of 105 children (11 males and 94
females) (G0), aged between 5 and 13 years, for
diagnosis of suspected CD, belonging to the Pae-
diatric Gastroenterology-Endoscopy Unit of PTV
Hospital, University of Rome “Tor Vergata”. 
Subjects G0 was carried out blood sampling (T0)
to verify the presence of the anti-tTG auto-anti-
bodies, anti-gliadin deaminated antibodies
(AGA) and anti-endomysium antibodies (EMA).
Those positive resulted (no.17, including 2
males and 15 females, aged between 5.4 years
and 12.10 years, mean age of 9.36 years +/-2
months S.D.) have been included into the G1.
Subjects of G1 have been subjected to a second
blood sample (T1) and, in the same session, to a
collection of saliva through the procedure called
“passive drooling” for evaluating the anti-tTG
auto-antibodies.
The blood samples have been collected in BD Va-
cutainer sterile tubes test. Later, at the Department
of Molecular Biology of PTV Hospital, Universi-
ty of Rome “Tor Vergata”, the tubes test have been
centrifuged at 3500 rpm for 5 minutes at ambient
temperature; the serum, obtained by centrifuga-
tion, has been suspended again 2-3 times to be
completely uniformed and it has been divided into
two equal parts in Eppendorf tubes test, both num-
bered. The two test have been sealed and frozen at
a temperature of -80°C until assay.
The fluid saliva samples have been collected in
50 ml Falcon tubes test, hermetically closed.
Subsequently, the samples have been centrifuged
at 1000 rpm for 5 minutes at ambient tempera-
ture and frozen at a temperature of -80°C.
For each sample of serum and saliva we have ex-
amined the anti-tTG auto-antibodies.
The anti-tTG auto-antibodies in the serum have
been analyzed by enzyme immunoassay method
(ELISA). The values  of anti-tTG serum are con-
sidered negative between 0 and 5 μg/mL, weak
between 5 and 7 μg/mL and positive >7 μg/mL.
The anti-tTG auto-antibodies in the saliva have
been analyzed by a Enzyme Linked Immuno
Magnetic Electrochemical method (ELIME);
they have been examined with the Autolab po-
tentiostat GPSTAT-12 equipped with software
GPES (Ecochemie, Ultrecht, The Netherlands).
The test has been validated using an analysis of
15 repetitions of the same negative sample and
calculation of:
- Limit Of Detection (LOD) = medium + 3
Standard Deviation;
- Limit Of Quantification (LOQ) = medium +
10 Standard Deviation. 
The measured values are 1.5 UA/mL for the
LOD and of 3.7 UA/mL for the LOQ.
The values below the LOD are considered as
“definitely negative”, while the values above the
LOQ as “definitely positive”; the intermediate
values are considered as “doubtful”.
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It has been chosen a value so high for the LOQ
because there have been problems in the dis-
crimination of values with a low title antibody
and therefore we have preferred to classify as
positive only those clear samples.
Subsequently, the subjects of G1, positive result-
ed for the presence of anti-tTG antibodies in the
serum, have been subjected to a gastroscopy
with a sampling of intestinal villi. 
The patients positive resulted to a gastrointesti-
nal biopsy have been introduced into the system
of a gluten-free diet (G2) (10 children, female,
aged between 5.4 and 12.4 years, mean age 9.1
years +/- 2.32 months S.D.). After six months
from the beginning of the gluten free diet, the
children belonging to G2 have been subjected to
an additional amount of saliva (T2), to verify the
utility of the anti-tTG salivary as a diagnostic
marker of CD and index for the follow-up of
gluten free therapy.
Moreover, it has been done a second sample of
salivary fluid even to children negative resulted
to the second blood sample (G3), but positive to
the first one (T0) and therefore considered poten-
tially coeliac (7 children, including 2 males and
5 females, aged between 6.5 and 12.10 years,
mean age 9.8 years +/- 2.25 months S.D). 
Results
Out of a total 105 paediatric patients (11 males
and 94 females, aged between 5 and 13 years)
(G0) subjected to a first blood sample (T0) for a
suspected diagnosis of CD in order to verify the
presence of anti-tTG antibodies, anti-gliadin
deaminated antibodies (AGA) and anti-endomy-
sium antibodies (EMA), only 17 have been re-
sulted positive (16.2%) (G1).
At the time of clinical observation, the G1 (2
males and 15 females) had an age between 5.4
and 12.10 years, with a mean age of 9.36 years
+/- 2 months S.D.
Regarding the evaluation obtained in the second
blood sample (T1) of the anti-tTG auto-antibod-
ies in the serum of the patients belonging to G1,
the results have showed that 10 children (G2) on
17 have demonstrated positivity to the anti-tTG
in the serum (Tab. 1) and therefore they have
been subjected to a sample of intestinal villi to
confirm the diagnosis of CD.
The incidence of the CD has been proved to be
equal to 9.5% (Fig. 1).
The results obtained demonstrate that 7 children
out of 17 are positive to the first sample of serum
Table 1 - Values  of anti-tTG in the serum and in the saliva in G1.
Patients anti-tTG Coeliac Disease anti-tTG anti-tTG presence
in the serum (µg/ml) in the saliva (Ua/ml) in the saliva
I sample
1 42,16 + 8,9 +
2 0,53 - 0,9 -
3 >100 + 8,9 +
4 2,5 - 0,6 -
5 >100 + 17,0 +
6 0,22 - 3,9 +
7 0,2 - 0,7 -
8 67,1 + 3,8 +
9 0,25 - 0,9 -
10 12,4 + 2,8 weakly positive
11 53,3 + 4,6 +
12 37,1 + 7,8 +
13 0,35 - 0,6 -
14 >100 + 2,0 weakly positive
15 0,27 - 4,0 +
16 86,4 + 11,7 +
17 22,9 + 6,9 +
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(T0) but negative to the second one (T1) (6.7%).
For this reason these subjects haven’t been sub-
jected to the sample of intestinal villi and they
haven’t been even classified as coeliac.
Since they have showed positivity to the anti-
tTG, even just once, we can consider them at the
beginning as potential coeliac, then as patients in
whom the disease could occur in a second time
of their lives. 
Regarding the evaluation of the anti-tTG in the
saliva (T1) of patients belonging to G1, the obtained
results show that 10 children out of 17 are “defi-
nitely positive” to the salivary anti-tTG (58.8%), 2
children are weakly positive (11.8%) and the ream-
ing 5 “definitely negative” (29.4%) (Tab. 1).
As regards the correspondence of the serum and
salivary anti-tTG in the G1, the results obtained
have shown that children positive to the anti-tTG
in the serum have anti-tTG even in the salivary
fluid (Tab. 2).
The sensitivity of the study is guaranteed 100%
and when we talk about “sensitivity” we mean
the measure of the frequency of a positive test
in the presence of the disease in question and it
is expressed as the percentage ratio between
true positives and total (true positives + false
negatives). 
The specificity is equal to 71.4%; even here
when we talk about “specificity” we mean the
measure of the frequency of the negative of a
test in the absence of the disease studied and it
is expressed as the percentage ratio between to-
tal and true negatives (true negatives + false
positives).
We’re talking about the 71.4% since there are 2
false positive; in fact 2 girls, belonging to the
Group G3, are negative to the anti-tTG of the
serum, but positive to the anti-tTG salivary. In
addition, the patients are characterized by the
positive genetic polymorphism, by a family his-
tory of CD and by symptoms referable to the dis-
ease; the 2 girls are healthy carriers of CD, since
they have the disease genes in the DNA and the
anti-tTG in the saliva.
The monitoring of the follow-up through the
salivary anti-tTG has predicted that the chil-
dren, belonging to the G1, have been subjected
to a further salivary fluid collection (T2), after
6 months from the first sample of salivary fluid
(Tab. 3).
The results obtained show the correspondence
between the first and the second sampling of
saliva in the same children (Tab. 4).
Looking at the results we can notice that in chil-
dren with CD the anti-tTG salivary are always
present, despite of the inclusion in the program
of the gluten-free diet.
The check of the anti-tTG in the serum is ex-
pected after 6 months from the start of the diet,
when it will be occurred the remission or not of
the disease and the presence of the markers in
the blood/saliva.
Figure 1 
Incidence of coeliac disease.
Table 2 - Correspondence of the serum and salivary anti-tTG
in G1.
Patients anti-tTG anti-tTG
in the serum in the saliva
1 + +
2 - -
3 + +
4 - -
5 + +
6 - +
7 - -
8 + +
9 - -
10 + weakly positive
11 + +
12 + +
13 - -
14 + weakly positive
15 - +
16 + +
17 + +
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Discussion
The CD, seen as a systemic immunological disor-
der, can have therefore numerous influences on
the content of the saliva (8, 12). Lenander-Lu-
mikari has shown that individuals with CD secrete
lower amounts of IgA, IgG and amylase; in his
study, he hasn’t found significant differences be-
tween coeliac and healthy subjects, as also it has
been said more recently by Mina (8, 13). Some
studies, over the last decade, have also demon-
strated the presence of anti-tTG auto-antibodies in
the saliva of coeliac children (14-16). 
This study has took into consideration the anti-
tTG auto-antibodies in the saliva of 17 children
with suspected CD, in order to attest the useful-
ness of the salivary anti-tTG as diagnostic and
predictors markers of the CD.
The obtained results demonstrate the simultane-
ous presence of the anti-tTG both in the serum
and in the saliva of paediatric patients with sus-
pected CD. In particular, in all children that have
shown only later such pathology (100%), the
saliva, as indeed also the serum, contained the
anti-tTG even before the clinical onset of the CD
(Tab. 2). This is also linked to the data reported
recently by Bonamico who, on a sample of 32
coeliac children (11 males and 21 females, aged
between 5.8 and 8.7, mean age 7.4 years) shows
the presence of the anti-tTG in the saliva. In par-
ticular, over the whole sample, 31 children have
showed correspondence with the anti-tTG both
in the serum and the salivary fluid, thus con-
Table 4 - Correspondence of anti-tTG in the saliva between the first and the second sample.
Patients anti-tTG anti-tTG anti-tTG anti-tTG
in the saliva in the saliva in the saliva in the saliva
(Ua/ml) I sample (Ua/ml) II sample
I sample II sample
1 8,9 + 2.3 weakly positive
2 0,9 - 1.8 -
3 8,9 + 5.6 +
4 0,6 - 2.4 -
5 17,0 + 33.6 +
6 3,9 + 5.4 +
7 0,7 - 1.4 -
8 3,8 + 4.9 +
9 0,9 - 1.3 -
10 2,8 weakly positive 4.1 +
11 4,6 + 3,9 +
12 7,8 + 11,8 +
13 0,6 - 1,3 -
14 2,0 weakly positive 4,4 +
15 4,0 + 5,6 +
16 11,7 + 5,8 +
17 6,9 + 8,4 +
Table 3 - Values  of anti-tTG in the saliva in G1 after 6 months.
Patients anti-tTG in anti-tTG presence
the saliva (Ua/ml) in the saliva
II sample
1 2,3 weakly positive
2 1,8 -
3 5,6 +
4 2,4 -
5 33,6 +
6 5,4 +
7 1,4 -
8 4,9 +
9 1,3 -
10 4,1 +
11 3,9 +
12 11,8 +
13 1,3 -
14 4,4 +
15 5,6 +
16 5,8 +
17 8,4 +
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firming the hypothesis that the saliva can be a
valuable help for diagnostic screening of such
pathology (11). However, a previous study, con-
ducted by Baldas, sayed that the saliva, because
of its low sensitivity, couldn’t be considered as a
source of the typical auto-antibodies of the CD
and for this reason such biological fluid couldn’t
be used for diagnostic purposes for the earlier
interception of the disease (17). 
Before the discover of the salivary anti-tTG,
several studies have been carried out in order to
seek the specific salivary antibodies for the di-
agnosis of the CD; in particular anti-gliadin
deaminated antibodies (AGA) and anti-endomy-
sium antibodies (EMA) have been evaluated and
analyzed (18, 25).
As regards as the AGA, they are resulted to be in
possess, in general, of a low sensitivity and a
limited specificity and therefore less reliable for
diagnostic purposes. However the EMA have
been specifically examined in two studies, both
dated: in the first one, led by Lahteenoja in
1999, it is stated that the salivary EMA aren’t
useful for the diagnosis or for the follow-up of
the CD; in the second one, led by Di Leo, it is
declared that the salivary EMA have a high
specificity (100%) but low sensitivity (46.5%)
and therefore, they should be considered also
unreliable for the diagnosis of CD (23, 24).
This is the reason why in the present study it has
been used the ELIME’s method; it represents a
simple, reproducible, non-invasive test that has, in
addition, an excellent sensitivity for the screening
of CD, like the RIA method (Radio Immuno As-
say) used in the study of 2011 of Bonamico re-
garding paediatric coeliac patients (11).
Looking at the data obtained, regarding the cor-
respondence of the anti-tTG salivary between
the first (T1) and the second sampling (T2) of
salivary fluid in the G1, it is clear that:
- the anti-tTG, after 6 months from the begin-
ning of the exclusion diet, are always present
in 10 coeliac children (G2) and in the 2 girls
healthy carriers of CD (Tab. 4);
- 4 children out of 12 positive resulted before to
the anti-tTG salivary (T1), show a decrease in the
concentration of anti-tTG (33.3%), while 8 out
of 12 show an increase of the anti-tTG (66.7%).
The results consider a period of time of the exclu-
sion diet equivalent to 6 months, demonstrating
that the concentration of the anti-tTG salivary
can’t be used as an early parameter of monitoring
for the follow-up of the patients after only 6
months from the beginning of the gluten-free diet.
Surely a wider range, namely up to 9 months or
more, could be more significant, as it’s affirmed
by Bonamico in his study, in which it is demon-
strated that the salivary anti-tTG can be used for
the follow-up of the disease, because after 9
months or more from the beginning of the exclu-
sion diet, 50% of paediatric patients with CD has
low levels of both anti-tTG salivary than serum
(16). In this study, it has been further corroborated
the hypothesis that the presence of salivary anti-
tTG after the beginning of the exclusion diet, can
reveal a poor adherence (16). In fact, after one
year of the gluten-free diet, the negativity of the
EMA and anti-tTG is indicative of a strict adher-
ence to it, while the positivity of the AGA, EMA
and anti-tTG is a symptom of poor adhesion (26).
Conclusions
The results obtained from this study have shown
how it could be possible to make a simple, repro-
ducible, non invasive, inexpensive and highly sen-
sitive screening of the CD using the saliva of pae-
diatric patient with suspected CD. Therefore, it’s
possible to say that the saliva and the presence of
anti-tTG auto-antibodies may be considered, like
other signs and clinical symptoms, intra and extra
oral; also like the results produced by the diagnos-
tic gastroenterology protocol and in addition like a
useful diagnostic dental markers, used for a first
screening of the disease, having, as it has been
demonstrated, a predictive and early value than
anti-tTG which are in the serum.
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